ANDA 40662, held by Bedford Laboratories. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 40662 (Methylprednisolone Sodium Succinate), held by Bedford Laboratories, was first approved by FDA on Feb 21, 2007, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 21, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone Sodium SuccinateEQ 40MG BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters